Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
NPCE Transcript
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript
Positive3-3
NeuroPace's earnings call reveals strong financial performance with significant revenue and gross margin growth, positive adjusted EBITDA, and reduced net loss. The raised revenue and gross margin guidance for 2025 further indicates optimism. Despite increased operating expenses, the strategic focus on RNS and upcoming FDA submissions, combined with favorable analyst sentiment, supports a positive outlook. The Q&A section highlights the potential of generalized epilepsy opportunities and Project CARE's growth contribution, reinforcing positive sentiment. Given these factors, a positive stock price reaction is expected over the next two weeks.
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary shows positive revenue and gross margin guidance, strong clinical trial results, and AI tool launches. Despite some uncertainties in the Q&A, such as lack of specific milestones in partnerships and unclear responses, the raised guidance and strategic initiatives suggest a positive outlook. The positive sentiment is further supported by optimistic growth expectations and strategic focus on RNS expansion. Given these factors, the stock price is likely to experience a positive movement in the short term.
NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call highlights strong financial performance with a 24% revenue increase, positive RNS sales growth, and a strategic focus on high-margin products. Despite a net loss, improved cash flow and sufficient liquidity are positive indicators. The Q&A section reveals confidence in growth targets, strong clinical data, and potential partnerships, boosting sentiment. However, a modest step-down in growth guidance and uncertainties around therapeutic partnerships slightly temper optimism. Overall, the positive aspects outweigh the concerns, suggesting a positive stock price reaction.
NPCE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
